Experimental Vaccine Rolled Out in Rwanda to Treat Marburg VIRUS | ቤተ-ሙከራ አፍሪካ

https://rumble.com/v5iagb9-experimental-vaccine-rolled-out-in-rwanda-to-treat-marburg-virus.html

BITCHUTE VIDEO

► ማርቡርግ ቫይረስን ለማከም የሙከራ ክትባት በሩዋንዳ ተለቀቀ፤ አፍሪካ ቤተ-ሙከራ!

በምሥራቅ አፍሪካ 'ተከስቷል' የተባለው ማርቡርግ ቫይረስ ምንድን ነው? ምን ያህልስ አደገኛ ነው?

ሩዋንዳ ውስጥ በማርቡርግ ቫይረስ ወረርሽኝ ምክንያት በቀናት ውስጥ ቢያንስ የስምንት ሰዎችን ሕይወት ማለፉን የጤና ባለሥልጣናት አስታውቀዋል።

ይህ በጣም ተላላፊ የሆነው በሽታ ከኢቦላ ጋር ተመሳሳይ ነው። ምልክቶቹም ትኩሳት፣ የጡንቻ ህመም፣ ተቅማጥ፣ ማስታወክ እና አንዳንዴም ከፍተኛ የደም መፍሰስ ሲሆን በአጣዳፊ ለሞት ሊያበቃ የሚችል ነው።

ከቅርብ ዓመታት ወዲህ በመቶዎች የሚቆጠሩ ሰዎች በማርቡርግ በቫይረስ ተይዘው ለሞት ተዳርገዋል። ከሞላ ጎደል ሁሉም የሞቱት አፍሪካ ውስጥ ነው።

ሉሲፈራውያኑ የዓለማችን ፈላጭ ቆራጮች አፍሪካን የወረርሽኞች፣ የክትባቶች እና የመርዞች ቤተ-ሙከራ ለማድረግ ባላቸው ዲያብሎሳዊ ተልዕኮ ዶ/ር ቴዎድሮስ አድሃኖም እንዲመሩት የተደረገው የዓለም ጤና ድርጅት እንደገለጸው ከሆነ የማርቡርግ ቫይረስ ከሚያጠቃቸው ሰዎች መካከል በአማካይ ግማሹን ይገድላል። ቀደም ሲል በተከሰቱት የበሽታው ወረርሽኞች ከተያዙት መካከል ከ ፳፬/24 እስከ ፹፰/88 በመቶ የሚሆኑትን ታካሚዎች ገድሏል።

ቫይረሱ ለመጀመሪያ ጊዜ የታወቀው በአውሮፓውያኑ 1967 በጀርመን ማርቡርግ እና ፍራንክፈርት እንዲሁም በሰርቢያ ቤልግሬድ በተከሰቱት ወረርሽኞች ሲሆን፣ 31 ሰዎች በቫይረሱ ከተያዙ በኋላ ሰባቱ በበሽታው ምክንያት ለህልፈት ተዳርገዋል።

የማርቡርግ ቫይረስ በአንጎላ፣ ዲሞክራቲክ ሪፐብሊክ ኮንጎ፣ ኢኳቶሪያል ጊኒ፣ ጋና፣ ኬንያ፣ ደቡብ አፍሪካ፣ ታንዛኒያ እና ኡጋንዳ የጉዳት ገዳይነት መጠን ከ፳፬/24 እስከ ፹፰/88 በመቶ ደርሷል።

👉 ለ ማርቡርግ ቫይረስ/MVD የተፈቀደ ህክምና ወይም ክትባት የለም; ሆኖም አፍሪካ የክትባት ቤተ-ሙከራችን ናት።

🔥 መሬት ዜሮ - ኢቦላ፣ ኩፍኝ፣ ፖሊዮ፣ ቴታነስ፣ ማርበርግ? 🔥

😢😢😢ዋይ! ዋይ! ዋይ! 😠😠😠

►“ለ ማርቡርግ ቫይረስ/MVD የተፈቀደ ሕክምና ወይም ክትባት የለም፤ ሆኖም፣ በርካታ ፋርማሲዩቲካል እና እጩ የ ማርቡርግ ክትባቶች/MVD ክትባቶች በምርመራ ላይ ናቸው። በአፍሪካ!

► የሩዋንዳው የማርቡርግ ወረርሺኝ በቁጥጥር ስር መዋሉን የአፍሪካ የጤና ኃላፊ ተናገሩ።

በሩዋንዳ እንደ ኢቦላ የመሰለ የማርበርግ ትኩሳት በቁጥጥር ስር እንደሚውል እና ወደ ምስራቅ አፍሪካዊቷ ሀገር የጉዞ እገዳዎች አስፈላጊ እንዳልሆኑ የአፍሪካ ከፍተኛ የህዝብ ጤና ኤጀንሲ ሃላፊ ተናግረዋል ።

🔥 Ground Zero - Ebola, Measles, Polio, Tetanus, Marburg? 🔥

►“There is no approved treatment or vaccine for MVD; however, several pharmaceuticals and candidate MVD vaccines are under investigation.”

► Rwanda's Marburg outbreak is under control, Africa's health chief says.

The head of Africa’s top public health agency says that an outbreak of the Ebola-like Marburg fever in Rwanda is under control and that travel bans to the East African country are unnecessary.

Marburg Virus with case-fatality rates of 24%-to-88% occurring in Angola, Democratic Republic of the Congo (DRC), Equatorial Guinea, Ghana, Kenya, South Africa, Tanzania, and Uganda have officially struck nearly 600 people.

👉 There is no approved treatment or vaccine for MVD; however, AFRICA is our ViralVaxLab

► Suggested citation: European Centre for Disease Prevention and Control.

Implications of the Marburg virus disease outbreak in Rwanda for the EU/EEA, 2024 – 10 October 2024. ECDC: Stockholm; 2024.

THREAT ASSESSMENT BRIEF

Summary

This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and, although uncommon, it has the potential to cause epidemics with significant case fatality. All recorded MVD outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical equipment is required for transmission. The risk of infection is minimised when proper infection prevention and control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several pharmaceuticals and candidate MVD vaccines are under investigation.

Epidemiological situation

Marburg virus disease (MVD), formerly known as Marburg haemorrhagic fever, is a severe disease in humans caused by Marburg marburgvirus (MARV). Although MVD is uncommon, MARV has the potential to cause epidemics

with significant case fatality. All recorded MVD outbreaks have originated in Africa. MVD is not an airborne disease and is considered not to be contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical equipment is required for MARV transmission. For more information on the symptoms and clinical picture of MVD please refer to ECDC’s ‘Factsheet for health professionals about Marburg virus disease’ .

On 27 September 2024, Rwanda reported that a number of MVD cases had been reported in the country. The first confirmed cases were detected when patients in teaching hospitals were not responding to treatment and they were

further tested. The first cases detected were linked to the presumed index case who died in early September 2024 . As of 9 October 2024, 58 cases, including 13 deaths and 12 recoveries, have been reported.

Based on limited information available for 36 cases reported as of 2 October 2024, they had been reported from eight of Rwanda’s 30 districts. The majority of cases were in healthcare workers (80%) and belong to the same

cluster in linked healthcare facilities in Kigali.

On 5 October 2024, the Sabin Vaccine Institute provided 700 doses of the investigational vaccine against Marburg virus (MARV) to Rwanda. The candidate vaccine is based on replication deficient chimpanzee adenovirus type 3 (cAd3), expressing MARV surface glycoprotein (GP). On 6 October 2024, vaccinations for healthcare workers in Kigali started as part of a Phase 2 rapid response open-label study .

_______

_______